CorMedix (CRMD) Stock Forecast & Price Target

Cormedix Inc. demonstrates a positive outlook anchored by the anticipated expansion of its DefenCath product, particularly with the integration into total parenteral nutrition (TPN), which is expected to significantly enhance revenue potential beyond current valuations. The company's guidance for DefenCath sales in 2027 projects a range of $100 million to $140 million, supported by the anticipated improvements in pricing and reimbursement for hemodialysis. Additionally, the successful integration of the Momenta acquisition, which adds approximately $140 million in proforma revenue and has already realized over $35 million in operating synergies, positions Cormedix as a more diversified and robust player in the specialty pharmaceutical market.

Cormedix Inc's outlook remains cautious due to its 2026 revenue guidance, which falls significantly short of both analyst expectations and previous estimates, particularly for its primary product, DefenCath. The company's projected 2026 sales of $150MM-$170MM for DefenCath are notably lower than the consensus forecast of $298MM, indicating potential challenges in achieving market penetration amid competition from generics. Additionally, market research highlights high discontinuation rates of azole-based regimens such as Bactrim, further exacerbating concerns about DefenCath's ability to sustain demand in an increasingly competitive environment.